Has Ali Mansour, MD received payments from drug or device companies?

Yes. Drug and device makers reported $58,257 in general payments to Ali Mansour, MD across 171 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ali Mansour, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ali Mansour, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ali Mansour, MD

Internal Medicine · Bronx, NYNPI 1427279017

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $36,200 of the $58,257 with a category attached, or 62.1%. United Therapeutics Corporation accounts for 81.6% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $22,903, more than ten times the $2,001 reported in 2019. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$58,257in general payments, 2019–2025

Across 171 payments — averaging $340.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

United Therapeutics Corporation$48K
Intuitive Surgical$3K
Boehringer Ingelheim$2K
Steris Corporation$2K
Pulmonx Corporation$1K
Ambu A/s$550
plus $2K from 19 others

$560,257in research payments, 2019–2025

Across 193 payments — averaging $2902.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

United Therapeutics Corporation$474K
Sanofi US Services Inc.$65K
Astrazeneca UK Limited$21K

What the payments were for

Consulting fees$5,55010%
Speaking & faculty fees$36,20062%
Travel & lodging$8,44314%
Food & beverage$4,8948%
Education$3,1705%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
United Therapeutics Corporation	84	$47,550
Intuitive Surgical	3	$3,064
Boehringer Ingelheim	9	$2,094
Steris Corporation	4	$1,812
Pulmonx Corporation	7	$1,256
Ambu A/s	1	$550
Insmed, Inc.	7	$264
Takeda Pharmaceuticals U.S.A., Inc.	10	$240
Kamada Ltd.	2	$239
Actelion Pharmaceuticals US, Inc.	6	$209
Novo Nordisk	7	$164
ANI Pharmaceuticals, Inc.	5	$139
Paragonix Technologies, Inc.	3	$114
Sunovion Pharmaceuticals Inc.	5	$83
Stryker	2	$77
Electromed, Inc.	4	$63
Verona Pharma, Inc.	2	$61
La Jolla Pharmaceutical Company	1	$61
Regeneron Healthcare Solutions, Inc.	1	$56
Baxter Healthcare	2	$50
Philips North America LLC	2	$46
Bard Peripheral Vascular, Inc.	1	$21
Ambu Inc.	1	$17
Mauna Kea Technologies, Inc.	1	$15
Lilly USA, LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,257 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York →

Medicare billing

Part B allowed, 2024

$51,089

Medicare patients

103

Services billed

354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Acyclovir	11	$237

Paid to pharmacies, not to this prescriber.

Other internal medicine in Bronx

Jason LeiderBronx$694K
Bulent AtacBronx$647K
Timothy KanterBronx$630K
Shervin MortazaviBronx$374K
Elizabeth Jenny-AvitalBronx$185K
Meyer HalberstamBronx$143K
David DoveEast Hampton$12.3M
Bruce BergerBrooklyn$3.4M
Nicholas RobinsonBuffalo$2.9M
Stephen SaletanNew York$2.6M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →